Dec 17 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE RESULTS OF PHASE 3 STUDY EVALUATING AMPHORA FOR HORMONE-FREE BIRTH CONTROL.EVOFEM BIOSCIENCES INC - Q2 2019 NEW DRUG APPLICATION (NDA) RESUBMISSION PLANNED.EVOFEM BIOSCIENCES INC - TOP-LINE PHASE 3 DATA DEMONSTRATE 86.0% EFFICACY, WHICH MET PRIMARY STUDY ENDPOINT.EVOFEM BIOSCIENCES - MINIMAL SIDE EFFECTS REPORTED BY AMPOWER STUDY PARTICIPANTS; NO SERIOUS TREATMENT-RELATED ADVERSE EVENTS REPORTED.EVOFEM BIOSCIENCES - IF NDS IS APPROVED, PLAN TO COMMERCIALIZE MVP-R FOR BIRTH CONTROL IN JAN 2020.EVOFEM BIOSCIENCES - IF NDA IS APPROVED, PLAN TO COMMERCIALIZE MVP-R FOR BIRTH CONTROL IN JAN 2020 (CORRECTS TYPO).
Full Article
Aug 2 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $1.11.Q2 EARNINGS PER SHARE VIEW $-0.48 -- THOMSON REUTERS I/B/E/S.EVOFEM - PHASE 3 TRIAL OF AMPHORA FOR HORMONE-FREE CONTRACEPTION CONTINUES TO MOVE AHEAD OF SCHEDULE; TOP LINE DATA NOW EXPECTED IN LATE 2018.UNRESTRICTED CASH INCREASED TO $22.8 MILLION AT JUNE 30, 2018, AS COMPARED TO $5.0 MILLION AT MARCH 31, 2018.
Full Article
May 22 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.EVOFEM BIOSCIENCES INC - SHARES AND PRE-FUNDED WARRANTS ARE BEING SOLD AT $4.69 PER SHARE AND $4.68 PER PRE-FUNDED WARRANT, RESPECTIVELY.
Full Article
May 16 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES FILES FOR OFFERING UP TO 8 MILLION SHARES OF CO'S STOCK, COMMON WARRANTS TO BUY AGGREGATE OF 1.6 MILLION SHARES OF CO'S COMMON STOCK.
Full Article
April 24 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.EVOFEM BIOSCIENCES INC - LAUNCH OF AN UNDERWRITTEN PUBLIC OFFERING OF $40.0 MILLION OF ITS COMMON STOCK.
Full Article
April 6 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES FILES FOR COMMON STOCK OFFERING OF UP TO $57.5 MLN - SEC FILING.
Full Article
Oct 17 (Reuters) - Neothetics Inc :Neothetics says if merger agreement with Evofem Biosciences terminated under specified circumstances, co to pay Evofem termination fee of up to $1.5 mln.
Full Article
Oct 17 (Reuters) - Neothetics Inc :Neothetics Inc and Evofem Biosciences, Inc. announce merger agreement to create Women’S health company.Neothetics Inc - privately-held Evofem Biosciences will merge with a wholly-owned subsidiary of Neothetics in an all-stock transaction.Neothetics - Invesco Asset Management entered securities purchase agreement to acquire additional $20 million of common stock in combined Co.Neothetics Inc - transactions have been approved by board of directors of both companies.Neothetics - Neothetics will be renamed Evofem Biosciences and will be under leadership of Evofem Biosciences' CEO Saundra Pelletier.Neothetics Inc - merger exchange ratio assumes $171.4 million in value of Co's common stock will be issued to Evofem Biosciences stockholders in merger.Neothetics - current Neothetics stockholders to own about 13% of combined company & current Evofem stockholders to own about 87% of combined company.Neothetics Inc - merger exchange ratio assumes $28.6 million in value of common stock being retained by Neothetics stockholders.Neothetics Inc - following merger, company will be led by Saundra Pelletier as chief executive officer.
Full Article
Earnings vs. 
Estimates